{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/08/3270148/0/en/MAIA-Biotechnology-Expects-Recent-33-Million-Capital-Raise-to-Fully-Fund-Ongoing-Pivotal-Phase-3-Trial-of-Novel-Telomere-Targeting-Anticancer-Therapy.html", "message": "News view counter 653320 successfully enlarged"}